Covid-19

#Covid-19 #Immunology / Virology & Vaccines #RNA

SARS-CoV-2 mutations do not appear to increase transmissibility

None of the mutations currently documented in the SARS-CoV-2 virus appear to increase its transmissibility in humans, according to a study led by UCL researchers. The analysis of virus genomes from over 46,000 people with COVID-19 from 99 countries is published in Nature Communications. First and corresponding author Dr Lucy… Read More

#Covid-19 #Editor's Choice #News

#Covid-19 #Immunology / Virology & Vaccines

Moderna to supply UK government with an extra 2 million vaccine doses

Moderna will supply the UK government with an additional 2 million doses of mRNA-1273, Moderna’s vaccine candidate against COVID-19, beginning in March 2021. The UK government has now secured 7 million doses of mRNA-1273. “We appreciate the collaboration with the UK government as with many other governments and other key… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

COVID-19 Peer Hub combats vaccine avoidance amid pandemic

From March to April 2020, more than 50% of immunisation programmes around the world have reported significant disruptions to their vaccination services. Developed and delivered by The Geneva Learning Foundation, and supported by the Bill & Melinda Gates Foundation, the COVID-19 Peer Hub programme is connecting more than 4000 immunisation… Read More

#Covid-19 #News

#Clinical trials #Covid-19 #Therapeutics

The 100 year-old therapy that may prevent COVID-19 after exposure to the virus

Most media and public attention during the pandemic has focused upon efforts to develop an effective vaccine to prevent COVID-19, which is caused by the novel coronavirus SARS-CoV-2. Some attention has been paid to investigational therapeutics for treating infected patients, such as the antiviral drug remdesivir or the corticosteroid dexamethasone,… Read More

#Covid-19 #Editor's Choice #News

#Covid-19 #Drug discovery #Therapeutics

New flu therapy may help against COVID-19

A new therapy for influenza virus infections that may also prove effective against many other pathogenic virus infections, including HIV and COVID-19, has been developed by Purdue University scientists. In an average year, more than 2 million people in the United States are hospitalised with the flu, and 30,000 to… Read More

#Covid-19 #News

#Covid-19 #Pharmaceutical #Research & development

UK pharma sector R&D spending at 8-year high

R&D spending in the UK pharmaceutical sector has jumped 6.9% annually to an eight-year high, analysis of the latest ONS data by R&D tax relief specialist Catax shows. Total pharmaceutical industry spending on R&D rose to £4.8bn last year, an increase of £306m from the £4.5bn recorded a year earlier1. Read More

#Editor's Choice #News #Trends & Analysis

#Clinical trials #Covid-19 #Immunology / Virology & Vaccines

Oxford COVID-19 vaccine 70% effective

The University of Oxford, in collaboration with AstraZeneca, has announced interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection. Following the trial reaching the target for interim analysis, the independent Data… Read More

#Covid-19 #Editor's Choice #News #Trending News

#AI / data analytics / healthtech / informatics #Covid-19

Collaborative AI effort unravelling SARS-CoV-2 mysteries wins prestigious prize

The Association for Computing Machinery (ACM) awarded its first ACM Gordon Bell Special Prize for High Performance Computing-Based COVID-19 Research to a multi-institution research team that included the US Department of Energy’s (DOE) Argonne National Laboratory. The team was singled out for its work, ​AI-Driven Multiscale Simulations Illuminate Mechanisms of… Read More

#Covid-19 #News

#Clinical trials #Covid-19 #Immunology / Virology & Vaccines

Oxford coronavirus vaccine produces strong immune response in older adults

The ChAdOx1 nCov-2019 coronavirus vaccine, developed by teams at the University of Oxford, has been shown to trigger a robust immune response in healthy adults aged 56-69 and those over 70 years of age. The data, published today in The Lancet, suggest that one of the groups most vulnerable to serious… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Clinical trials #Covid-19 #Vaccines

Pfizer and BioNTech conclude Phase III study of Covid-19 vaccine, showing 95% efficacy

Pfizer and BioNTech have announced that after conducting the final efficacy analysis in their ongoing Phase III study, their mRNA-based COVID-19 vaccine candidate, BNT162b2, met all of the study’s primary efficacy endpoints. Analysis of the data indicates a vaccine efficacy rate of 95% in participants without prior SARS-CoV-2 infection (first… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines

European Medicines Agency begins rolling review of Moderna’s vaccine candidate

The European Medicines Agency (EMA) human medicines committee (CHMP) has started a rolling review of Moderna’s mRNA-1273 vaccine candidate against COVID-19. This follows confirmation of eligibility of mRNA-1273 for submission on October 14, 2020. On 16 November Moderna announced that the independent, US NIH-appointed Data Safety Monitoring Board (DSMB) for… Read More

#Covid-19 #News

#Covid-19 #Immunology / Virology & Vaccines

Moderna announces supply agreement with UK government for COVID-19 vaccine

Moderna has announced a supply agreement with the UK government to supply mRNA-1273, its COVID-19 vaccine candidate, beginning in March 2021 if it is approved for use by UK regulatory authorities. This agreement comes as the UK continues its efforts to secure access to safe and effective COVID-19 vaccines. “We… Read More

#Covid-19 #Editor's Choice #News #Trending News